Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Abgenix, Inc. (ABGX) -- Ignore unavailable to you. Want to Upgrade?

To: kenhott who wrote (527)	11/8/2005 3:41:05 PM
From: serendipity101	Read Replies (2) \| Respond to of 590

RE: the decision points should be: efficacy, costs, and quality of life. I agree, however... i'd also love to see the biotech industry focus more efforts on improving in vitro diagnostic technologies in conjunction with genomics and proteomics. i'm a believer in proactive tactics involving the future of diagnostics. don't you think this would further fuel the revolution against cancer and truly improve efficacy, drive down costs and enhance quality of life? Prognosis is the future.

To: kenhott who wrote (527)	11/9/2005 3:06:34 AM
From: DewDiligence_on_SI	Respond to of 590

I agree with you about IMCL’s patent (it’s not worth much), but I disagree on the compendium listings for Pani with chemo: >Oncologists will use it and AHFSDI and/or USPDI will pick up the activities resulting in recommendation.< When, if ever, has AHFS or USP listed a drug for a regimen and setting (Pani+chemo in third-line CRC) where there are not even phase-2 data? I think it will be a considerable amount of time before Pani is reimbursed in this regimen/setting, which is currently Erbitux’s main revenue source.